Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
4503 On Other Exchanges
Symbol
Exchange
4503 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

astellas pharma inc (4503) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ASTELLAS PHARMA INC (4503)

Related News

No related news articles were found.

astellas pharma inc (4503) Related Businessweek News

View More BusinessWeek News

astellas pharma inc (4503) Details

Astellas Pharma Inc. manufactures, markets, and imports/exports pharmaceutical products worldwide. The company focuses on the therapeutic areas of urology, immunology and infectious diseases, oncology, neuroscience, and diabetes mellitus complications and kidney diseases. The company offers immunosuppressants, including Prograf, and Advagraf/ Graceptor/ ASTAGRAF XL; Vesicare and Betanis/Myrbetriq/BETMIGA for overactive bladder treatment; and Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia. It also provides Funguard/MYCAMINE, a candin antifungal agent; Protopic for atopic dermatitis; Eligard, XTANDI, and Gonax for prostate cancer treatment; Micardis, including Micombi and Micamlo BP for hypertension; Celecox, an anti-inflammatory agent; Symbicort for adult bronchial asthma and chronic obstructive pulmonary disease; Geninax for oral quinolone antibiotic; Bonoteo for osteoporosis; Cimzia for the treatment of adult patients with rheumatoid arthritis; and Suglat for type two diabetes treatments. In addition, the company offers Lipitor products for the treatment of hypercholesterolemia; Gaster for peptic ulcers and gastritis; Myslee for insomnia; Seroquel for schizophrenia; Regnite for restless legs syndrome; Kiklin for hyperphatemia treatments, as well as Lexiscan and Adenoscan, which are pharmacologic stress agents; and Tarceva for the treatment of lung and pancreatic cancers. Further, it provides Acofide for functional dyspepsia; Bisono Tape, a transdermal hypertension medication; diarrhea-predominant OD tablets; and dificlir for clostridium difficile infections. It has a strategic alliance with Amgen Inc. and ClearPath Development Company; and collaborative agreements with Immuno-Biological Laboratories Co., Ltd., Cytokinetics, Inc., Mitokyne, Inc., QIAGEN N.V., Dana-Farber Cancer Institute, and Ventana Medical Systems, Inc. The company was founded in 1923 and is headquartered in Tokyo, Japan.

17,113 Employees
Last Reported Date: 06/17/15
Founded in 1923

astellas pharma inc (4503) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥182.0M
Chief Administrative Officer, Chief Complianc...
Total Annual Compensation: ¥88.0M
Compensation as of Fiscal Year 2015.

astellas pharma inc (4503) Key Developments

Astellas Appoints Julie Monzo as Senior Manager, Global Medical and Development Communications

Astellas announced that Julie Monzo has been appointed to the newly created role of senior manager, Global Medical and Development (GMD) communications, as part of the Corporate Affairs department. Monzo will report to Andrew Lewis, head of communications, GMD, and will lead both internal and external global communications programs for the functional groups that comprise GMD, including Clinical Development, Medical Affairs, Pharmacovigilance, Quality Assurance and Regulatory Affairs. Monzo most recently served as senior manager, enterprise communications and public relations at the College of American Pathologists.

Astellas Pharma, Inc. Announces Results from Phase IIIb Overactive Bladder Trial

Astellas Pharma, Inc. has announced results from its Phase IIIb BESIDE clinical trial, which demonstrated that solifenacin, or SOLI, with mirabegron, or MIRA, as an add-on therapy, or ADD-ON, was effective compared to solifenacin monotherapy in incontinent overactive bladder, or OAB, patients. The results of the BESIDE trial showed that the ADD-ON group achieved its primary efficacy endpoints. In the BESIDE trial, the mean number of daily incontinence episodes was reduced by 1.80 episodes in OAB patients given solifenacin 5 mg with mirabegron 50 mg (dosage was increased from 25 mg after 4 weeks) as an add-on therapy compared to a reduction of 1.53 episodes seen with SOLI 5 mg monotherapy. The difference between the two treatments of approximately 0.26 was statistically significant (P=0.001). The mean number of daily micturitions was reduced by 1.59 micturitions in the ADD-ON group compared to 1.14 micturitions with SOLI 5 mg (the difference of 0.45 was statistically significant [P<0.001]). In addition, ADD-ON treatment was both non-inferior and superior to SOLI 10 mg for daily reduction in micturitions. ADD-ON treatment also was superior to SOLI 5 mg and 10 mg monotherapy for improvement in urine volume voided per micturition. At least one treatment emergent adverse event (TEAE) was reported by 35.9% receiving ADD-ON therapy, 39.4% receiving SOLI 10 mg and 33.1% receiving SOLI 5 mg, with the most common (occurring in at least 2% of patients) being dry mouth, constipation and peripheral edema. Serious adverse events (SAEs) were reported by 1.8% of patients receiving ADD-ON therapy, 2.1% receiving SOLI 10 mg and 1.2% receiving SOLI 5 mg. The ADD-ON group reported a lower incidence of dry mouth than the SOLI 10 mg group (5.9% versus 9.5%), and a similar incidence as the SOLI 5 mg group (5.6%). The incidence of constipation in the ADD-ON group was 4.6% versus 4.7% and 3.0% for the SOLI 10 mg and SOLI 5 mg groups, respectively. The Phase IIIb BESIDE study is a randomized, double-blind, international study designed to evaluate the efficacy and safety of mirabegron as add-on therapy to solifenacin in incontinent OAB patients. Study patients received SOLI 5 mg monotherapy for 4 weeks; subjects with inadequate response to treatment (i.e., patients who still experienced one or more incontinence episodes during a three-day diary period) were then randomized to either SOLI 5 mg, SOLI 10 mg, or SOLI 5 mg in combination with MIRA 25 mg, which was increased to MIRA 50 mg after 4 weeks. Overall 2,174 patients were randomized to the ADD-ON group (n=727), SOLI 5 mg (n=728) or SOLI 10 mg (n=719). The primary efficacy endpoint was change from baseline to the end of treatment (EoT) in mean number of incontinence episodes/24 hours. All three treatment arms investigated in this study appeared to be well-tolerated, and the adverse event (AE) profile with ADD-ON treatment was generally consistent with the known profiles of SOLI and MIRA. Vital signs in this group showed no additive or synergistic effects beyond those known for either monotherapy.

Astellas Pharma Inc. and Anokion SA to Collaborate on Immune Tolerance Therapeutics

Astellas Pharma Inc. and Anokion SA announced an agreement to collaborate in the fields of type 1 diabetes and celiac disease. Key components of the agreement include: A new company, Kanyos Bio, Inc., has been created to develop clinical candidates in the two selected indications, with an option for Astellas to add a third autoimmune indication as part of the collaboration; Astellas will provide non-dilutive research funding to Kanyos and holds an option to acquire Kanyos after reaching certain milestones; Total potential deal value of about $760 million includes R&D funding, option exercise and milestone payments; and Astellas will also participate, along with Anokion’s existing investors, in a $16 Million equity financing for Kanyos.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4503:JP ¥1,745.50 JPY +2.50

4503 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $141.51 USD -0.2737
Boston Scientific Corp $17.71 USD -0.10
CSL Ltd A$86.47 AUD +0.62
Mylan NV $67.69 USD +0.06
Solvay SA €123.95 EUR -1.65
View Industry Companies
 

Industry Analysis

4503

Industry Average

Valuation 4503 Industry Range
Price/Earnings 27.5x
Price/Sales 3.0x
Price/Book 2.8x
Price/Cash Flow 21.5x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTELLAS PHARMA INC, please visit www.astellas.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.